Does the Medical University of South Carolina (MUSC) in South Carolina offer on‑site genomic profiling, PSMA PET imaging, and 177Lu‑PSMA‑617 therapy for stage IV prostate cancer patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

MUSC Capabilities for Advanced Prostate Cancer Care

I cannot provide specific information about the Medical University of South Carolina's (MUSC) on-site capabilities for genomic profiling, PSMA PET imaging, or 177Lu-PSMA-617 therapy based on the evidence provided, as none of the guidelines, drug labels, or research studies contain institutional-specific information about MUSC's facilities or services.

What You Need to Know About These Services

For stage IV prostate cancer patients requiring these advanced diagnostics and therapeutics, you need to verify directly with MUSC whether they offer:

1. Genomic Profiling

  • Early biomarker testing is crucial before starting mCRPC treatment 1
  • HRR gene alterations (particularly BRCA1/2) are common in mCRPC and predict significant survival benefit with PARP inhibitor combinations 1
  • Testing should identify BRCA1/2, ATM, and other HRR alterations, plus MSI-H/dMMR status 1

2. PSMA PET Imaging

  • Required for 177Lu-PSMA-617 eligibility determination 2
  • FDA-approved radiotracers include Ga-68 PSMA-11, F-18 piflufolastat, and F-18 flotufolastat 3
  • PSMA PET demonstrates superior sensitivity and specificity compared to conventional imaging 2

3. 177Lu-PSMA-617 Therapy

  • FDA-approved for mCRPC patients with PSMA-positive imaging who have received prior ARPI and docetaxel 2
  • Requires multidisciplinary collaboration involving medical oncology, nuclear medicine, and radiation oncology 2
  • Treatment involves 6 cycles administered every 6 weeks at 7.4 GBq per cycle 1

How to Verify MUSC's Capabilities

Contact MUSC directly through:

  • Their cancer center's nuclear medicine department
  • Medical oncology division specializing in genitourinary cancers
  • Patient navigation services

Key questions to ask:

  • Do you have on-site PSMA PET/CT imaging capabilities?
  • Which PSMA radiotracers do you use?
  • Do you administer 177Lu-PSMA-617 therapy on-site?
  • What genomic testing platforms do you utilize?
  • Is there a multidisciplinary prostate cancer tumor board?

Geographic Considerations

Rural and underserved patients face significant barriers to accessing advanced prostate cancer care 4. If MUSC lacks these capabilities, alternative options include:

  • Referral to comprehensive cancer centers with theranostics programs
  • Clinical trial enrollment at institutions with PSMA-targeted therapy protocols
  • Telemedicine consultation with genomic testing coordination

The evidence strongly supports that these three components—genomic profiling, PSMA PET imaging, and 177Lu-PSMA-617 therapy—represent standard-of-care for appropriate mCRPC patients 1, 2, but institutional availability varies significantly across centers.

References

Related Questions

In a male patient with bone‑only metastatic castration‑resistant prostate cancer who has been heavily pretreated with docetaxel, continuous androgen deprivation therapy followed by orchiectomy, abiraterone (Zytiga), targeted radiation, sipuleucel‑T (Provenge), and ^177Lu‑PSMA‑617 (Pluvicto), and who started the investigational ligand‑directed degrader BMS‑986460 at 1 mg daily, does the recent PSA rise after a prior sustained decline indicate emerging resistance to BMS‑986460 rather than continued therapeutic benefit?
What is the prognosis for a patient with castration-resistant metastatic prostate cancer (CRPC) with multiple small tumors, including a lung tumor expressing Prostate-Specific Membrane Antigen (PSMA), who has shown a good response to the first Lutetium-177 (LU-177) infusion?
What are the eligibility criteria and treatment regimen for the VISION trial evaluating lutetium‑177‑PSMA‑617 in men with metastatic castration‑resistant prostate cancer?
Do Johns Hopkins, Mayo Clinic, Memorial Sloan Kettering, and MD Anderson meet the criteria for optimal stage IV prostate cancer care, including on‑site genomic profiling, PSMA PET imaging, and availability of 177Lu‑PSMA‑617 radioligand therapy and relevant clinical trials?
What are normal cardiac output values in adults and how are low and high output states defined and managed?
Do Johns Hopkins, Mayo Clinic, Memorial Sloan Kettering, and MD Anderson meet the criteria for optimal stage IV prostate cancer care, including on‑site genomic profiling, PSMA PET imaging, and availability of 177Lu‑PSMA‑617 radioligand therapy and relevant clinical trials?
What is a positive Hoover sign, and how does it apply to a migraine patient with brain fog and word‑finding difficulty?
How should I manage a patient with migraine and functional neurological disorder who presents with weakness and a positive Hoover sign on neurologist examination?
Do granulocyte colony-stimulating factor (G‑CSF) or blood transfusion cause an increase in eosinophil or lymphocyte counts?
In castration-sensitive metastatic prostate cancer, is orchiectomy or medical androgen-deprivation therapy with external-beam radiation more effective?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.